Sign in
Knowstox

Fundamentals snapshot

InflaRx N.V.

IFRX · NMS · Healthcare · Biotechnology

Current price

$1.32

52-week range

$0.80 - $2.95

Market cap

$194.53M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-1,229.82x Concerning

Net cash $177.27M. Interest coverage shows how many times profit covers the interest bill.

What this company does

InflaRx N.V.

InflaRx N.V. is a company that creates new medicines to help people with inflammatory diseases, like those caused by an overactive immune system. Their main product is a new drug in testing that aims to reduce inflammation. This matters because if their drug is approved, it could become a significant new treatment option for many patients.

Price history

How the share price has moved

—
Loading price history…

Is it cheap or expensive?

Fair value — vs current price $1.32

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $177.3M - more cash than debt. Interest coverage -1229.8x.

Net debt $-177.27M
Interest coverage -1,229.82x

InflaRx N.V. is healthier than 0 of 1 peers on balance-sheet leverage.

Healthy
Worse cushion Baseline Better cushion
IFRX BASELINE InflaRx N.V.

Total debt $936.68K Interest coverage -1,229.82x This is the baseline the peer rows are being compared against.

-1,229.82x

What you should know

The case for and against IFRX

0 Rewards 1 Risk

Rewards

Risks

  • Return on equity was -38.5% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-3.40x
P/B
1.18x
P/S
-19,258.10x
EV/EBITDA
-1.53x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
352,965.0%
Net margin
0.0%
ROE
-38.5%
ROA
-18.5%

Health

Liquidity and balance-sheet strength

Debt / equity
0.01x
Current ratio
8.22x
Quick ratio
7.95x
Total debt
$936.68K
Total cash
$178.21M

Growth

How the business has been compounding

Revenue TTM
$-11.36K
Revenue 5Y CAGR
—
EPS TTM
-0.56
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-39.70M
Free CF TTM
$-39.83M
FCF margin
350,757.6%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—